OT-551 is administered topically, developed by Othera Pharmaceuticals, Inc. (Exton, PA)⁽⁶³⁾.

This eyedrop contains a small molecule that downregulates the overexpression of the protein complex nuclear factor (NF)- B.

NF- B is a transcription factor that is highly activated when oxidative stress, inflammation, and angiogenesis occurs.

In preclinical models, OT-551 has demonstrated anti-oxidative, anti-inflammatory and anti-angiogenic activity.

These results support the development in diseases such as AMD and cataract.

OT-551 is the first eye drop to be tested in a clinical trial as a treatment for dry AMD.

There are 2 phase II, 2-year trials ongoing for patients with GA secondary to AMD^(64,65).